Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IG201
- Development stage
- Preclinical
- Lead developer
- Ingenium Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
IG201 is a preclinical-stage dual-payload Target Immune Stimulator (TIS) being developed by Ingenium Therapeutics for the treatment of slow-dividing and treatment-resistant cancers. Built on Ingenium's proprietary TIS platform, IG201 consists of a ROR1-directed antibody conjugated via a linker to two distinct payloads: an IL-21/15 fusion cytokine and TN13, a peptide-based p38 inhibitor. This dual-payload approach is designed to attack cancer cells through multiple pathways, stimulating anti-tumor immunity and modulating the tumor microenvironment (TME) to overcome the limitations of conventional antibody-drug conjugates (ADCs) and immunotherapies.
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on IG201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IG201.